Pharmax N. A

What Pharmax N. A does

Pharmax N.A. Inc. is a privately held pharmaceutical sourcing and distribution company founded in 2000 and headquartered in Pomona, California, with an operating footprint spanning North America, Europe, China, the Middle East, Latin America, and Southeast Asia. The company operates as an exclusive sales agent and regulatory agent for Chinese API manufacturers, supplying pharmaceutical active ingredients, nutraceutical ingredients, and cosmetic raw materials to regulated markets under US FDA and CEP certifications maintained since 2004. It serves multinational pharmaceutical companies (Merck, Bayer), animal health leaders (Elanco, Novartis, Zoetis, Phibro), nutraceutical manufacturers, and cosmetic companies, holding approved-vendor status with these enterprise buyers.

The product portfolio spans three divisions: Human Healthcare (vitamins, amino acids, APIs including oncology and cardiovascular, herbal extracts, excipients, marine biochemicals), Veterinary Products (anti-infectives, anti-parasitics, nutritionals, and dosage forms), and Trace Minerals (proprietary Hydroxy Metal Chloride series, Calimet hydroxy methionine chelates pioneered in China since 2002, and OMS-Optimal Mineral System compound premixes). Service offerings include regulatory support (DMF/VMF/EDMF filing, source qualification, cGMP auditing, CAPA), quality assurance via FDA-inspected laboratories, and logistics operations shipping to more than 30 worldwide destinations weekly from a US warehouse.

Revenue is generated through API and ingredient product sales, contract manufacturing service fees, and logistics services. Pricing is not publicly disclosed; customers contact sales directly. Go-to-market is event-driven, anchored by 20+ consecutive years of CPHI Worldwide exhibition participation and presence at over 10 major global pharmaceutical and nutraceutical trade shows annually, with dedicated US and China teams. The company has supported a sustained track record of FDA zero-483 inspection results across its Chinese contract manufacturer partners and achieved a landmark FDA NDA approval for Moxidectin API for the treatment of river blindness in 2018.

Name

Pharmax N. A

Legal name

Pharmax NA Inc.

Website

https://pharmaxus.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Pharmax N.A. Inc. is a privately held US-headquartered pharmaceutical sourcing firm that acts as exclusive sales and regulatory agent for Chinese API manufacturers, supplying FDA-approved APIs, nutraceutical ingredients, and proprietary trace minerals to multinational pharmaceutical, animal health, and nutraceutical companies since 2000.

Ownership category

akta.pro rank

Product category

Pharmaceutical Ingredient Distribution and Regulatory Services

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210), Chemical and Allied Products Merchant Wholesalers (4246)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Chemicals & Allied Products (5160)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

akta.pro secondary industries

Veterinary Pharmaceutical Wholesalers & Distributors (HLAMAIAA), Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Headquarters

HQ city

Pomona

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D, Infrastructure

Revenue model

1. API and Ingredient Product Sales: Pharmax N.A. Inc. generates revenue primarily through the sale of pharmaceutical active pharmaceutical ingredients (APIs), vitamins, supplements, nutraceutical ingredients, trace minerals, and cosmetic raw materials to regulated markets. The company acts as the exclusive sales agent or regulatory agent for Chinese API manufacturers, supplying products to multinational pharmaceutical companies, veterinary product companies, and nutraceutical/cosmetic manufacturers.
2. Contract Manufacturing Services: Pharmax offers contract manufacturing opportunities and regulatory support services, including DMF/VMF/EDMF filing, source qualification, cGMP auditing, CAPA, and quality engineering management. The company facilitates FDA/COS approval processes for its contract API manufacturing partners and earns service fees for regulatory support.
3. Logistics Services: The company's logistics department manages shipments to more than 30 worldwide destinations weekly, with a conveniently located warehouse in the US assuring timely delivery to customer facilities. Logistics services support the product sales and supply chain operations.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Pharmax N.A. Inc. is a pharmaceutical, nutraceutical, and cosmetic ingredient supplier acting as an approved vendor and exclusive sales/regulatory agent for Chinese API manufacturers serving regulated markets (US FDA and CEP). The company distributes APIs, vitamins, amino acids, trace minerals, and specialty ingredients across veterinary, human healthcare, and animal nutrition segments, and supports customers with regulatory filings (DMF/VMF/EDMF), cGMP auditing, CAPA, and logistics services from a US warehouse to 30+ worldwide destinations.

Product overview

Pharmax N.A. Inc. is a specialized pharmaceutical, nutraceutical, and cosmetic product supplier serving regulated markets since 2000. The company operates as a single unified offering with three interconnected product divisions: Human Healthcare Products (vitamins, supplements, APIs, herbal extracts, excipients, and oncology drugs), Veterinary Products (anti-infectives, anti-parasitics, nutritionals, and dosage forms), and Trace Minerals (hydroxy metal chlorides, amino acid chelates, and compound mineral premixes). The product portfolio also includes quality assurance, regulatory support, and logistics services. The company acts as exclusive sales agent or regulatory agent for major API manufacturers in China, providing complete strategic sourcing solutions for ANDA/ANADA/NADA needs. Key strengths are in vitamins, supplements, and FDA-approved pharmaceutical ingredients with contract manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Veterinary Products
• Human Healthcare Products
• Trace Minerals
• Quality Assurance Services
• Regulatory Support Services
• Logistics Services

Quantifiable outcome

• Over 100 meetings conducted with global clients and suppliers at CPHI Americas 2025
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered core.

• Medicines Development for Global Health (MDGH)coreStrategic or Co-development Partner · 24 July 2018Pharmax supplied the moxidectin API (manufactured by Livzon Group) for MDGH's New Drug Application to the US FDA for treatment of river blindness (onchocerciasis), an orphan disease. The NDA was approved by US FDA. MDGH received funding from the Global Health Investment Fund, backed by the Bill and Melinda Gates Foundation.
• NovartiscoreStrategic or Co-development PartnerPharmax identifies Novartis as one of its strategic partners in the animal health sector. The partnership involves the supply of pharmaceutical and nutraceutical products to regulated markets.
• ZoetiscoreStrategic or Co-development PartnerPharmax identifies Zoetis as one of its strategic partners in the animal health sector. Zoetis is a major global animal health company and Pharmax supplies products under this partnership.
• PhibrocoreStrategic or Co-development PartnerPharmax identifies Phibro as one of its strategic partners. Phibro Animal Health Corporation is a major animal health and mineral nutrition company.
• Livzon New North River Pharmaceutical Co., Ltd (LIVZON NNR)coreStrategic or Co-development PartnerStrategic partner and contract manufacturer. Pharmax provided on-site QA and regulatory support helping LIVZON NNR successfully pass US FDA GMP inspection in November 2015 with zero-483. Pharmax also supported this partner's moxidectin API supply for FDA NDA approval for river blindness treatment.
• NCPC Huanluan (Lincomycin HCl manufacturer)coreStrategic or Co-development PartnerContract manufacturer of Lincomycin HCl. Pharmax helped NCPC Huanluan successfully pass FDA re-audit with zero-483 in September 2009 and again in December 2015.
• CSPC Zhongrun Pharmaceutical (Inner Mongolia) Co., LtdcoreStrategic or Co-development PartnerContract manufacturer of Penicillin G Potassium. Pharmax's on-site QA and regulatory support helped CSPC Zhongrun successfully pass US FDA inspection in October 2012.
• Hebei Jianmin Starch Glucose Co., LtdcoreStrategic or Co-development PartnerLargest producer of OTC serial products in the world. Successfully passed US FDA inspection in November 2013 with Pharmax's strong support and guidance. Also passed FDA audit for Oxytetracycline with zero-483 in July 2016.
• Ningxia TairuicoreStrategic or Co-development PartnerContract manufacturer of Tylosin Tartrate. Successfully passed US FDA inspection in August 2014 with Pharmax's strong support and guidance.
• Inner Mongolia Changsheng Pharmaceutical Co., LtdcoreStrategic or Co-development PartnerContract manufacturer of Penicillin. Successfully passed US FDA inspection in June 2015 with Pharmax's strong support and guidance.
• Chongqing Southwest No.2 Pharmaceutical Factory Co., LtdcoreStrategic or Co-development PartnerContract manufacturer of Procaine Hydrochloride. Passed US FDA GMP onsite audit with zero-483 in July 2016 (second time, previously in 2012). Became the only procaine hydrochloride manufacturer that passed the US FDA certification. Pharmax assisted with FDA flight inspection in April 2017.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hovione: API contract development and manufacturing organization with its own global manufacturing footprint and active involvement in regulatory filings for partners. Overlaps with Pharmax on the regulated-API go-to-market and GMP-audit support side, though Hovione adds in-house manufacturing.
• Aceto Pharma / Aceto Corporation: Pharmaceutical intermediates and APIs distributor historically sourcing heavily from China and India for sale into US/EU regulated markets. Closest historical analog to Pharmax's China-sourcing and regulatory-support business model before its 2021 restructuring.
• Spectrum Chemical: US-based distributor of fine chemicals, APIs, and excipients to pharmaceutical and nutraceutical manufacturers. Comparable model: aggregation of multi-source API/ingredient lines sold into regulated end-markets, with cGMP warehousing and lot traceability.
• TCI Chemicals: Specialty chemicals manufacturer and global distributor supplying research-grade and pharma-grade chemicals to drug manufacturers and formulators. Comparable in distribution of regulated-market ingredients, broad SKU portfolio, and multi-region warehouse footprint.
• Parchem - Fine & Specialty Chemicals: Specialty-chemicals and pharmaceutical-ingredient distributor that sources APIs and intermediates from global manufacturers for sale into US/EU regulated markets. Directly overlaps Pharmax's role as a sales/regulatory agent between Asian producers and Western pharma buyers.
• Cayman Chemical: US-based supplier of APIs, biochemicals, and research compounds to pharmaceutical and academic customers. Comparable as a US-headquartered API distributor with deep catalogs across therapeutic categories and cGMP-grade offerings.
• Pfaltz & Bauer (Pfanstiehl): US manufacturer and global distributor of pharmaceutical-grade sugars, excipients, and APIs serving injectable and biopharma customers. Comparable as a US-headquartered pharma-ingredient specialist with multinational contract manufacturing relationships and regulated-market certifications.

Broad incumbents

• Alfa Aesar (Thermo Fisher Scientific): Global chemicals and materials supplier (now part of Thermo Fisher) serving pharma and research customers with a multi-source API and reagent catalog. Comparable in the regulated-ingredient distribution role, with very different scale and a broader product scope.
• Sigma-Aldrich (Merck KGaA / MilliporeSigma): Largest global life-science and pharma-ingredient supplier, offering extensive APIs, excipients, and reference materials to regulated customers. Comparable product breadth and regulated-market certifications; vastly larger scale and direct, in-house manufacturing.

Emerging players

• WuXi AppTec / WuXi STA: China-headquartered CRO/CDMO with Western-market regulatory expertise for Chinese-produced APIs. Comparable with Pharmax on the China-origin, FDA-licensed sourcing axis, though WuXi also performs contract manufacturing in-house rather than acting as a pure intermediary.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmax N. A